H1:IC31疫苗在结核分枝杆菌感染与未感染青少年中安全并诱导长效TNF-α+IL-2+CD4 T细胞应答:一项随机试验
这项观察者盲法II期临床试验在健康青少年中按结核分枝杆菌感染状态分层,评估以IC31为佐剂的H1融合蛋白疫苗(H1:IC31)的安全性与免疫原性。240名参与者随访224天,无论H1剂量或接种程序均未见明显安全性事件;接种诱导抗原特异性CD4 T细胞,未感染者优先产生Ag85B和ESAT-6特异性TNF-α+IL-2+CD4 T细胞,感染者仅Ag85B特异性此类细胞扩增。15μg H1:IC31接种两剂诱导的免疫应答幅度最大,被认为是最优方案。
要点
- H1:IC31在结核分枝杆菌感染与未感染青少年中均安全,未见明显安全性事件。
- 接种诱导抗原特异性CD4 T细胞,共表达IFN-γ、TNF-α和/或IL-2。
- 15μg H1:IC31接种两剂诱导的免疫应答幅度最大,被认为是最优方案。
核心结论
- H1:IC31在未感染和结核分枝杆菌感染青少年中安全且有免疫原性;15μg H1:IC31接种两剂诱导的免疫应答幅度最大,被认为是最优方案。
研究设计与样本
- 观察者盲法II期临床试验,纳入健康青少年并按结核分枝杆菌感染状态分层。
- 候选疫苗H1:IC31由Ag85B与ESAT-6的融合蛋白(H1)以IC31佐剂配制而成。
- 共招募240名参与者,随访224天;比较15μg或50μg H1蛋白接种一剂或两剂的局部与全身不良事件及诱导的T细胞应答。
主要发现
- 无论H1剂量或接种程序,均未见明显安全性事件。
- H1:IC31接种诱导抗原特异性CD4 T细胞,共表达IFN-γ、TNF-α和/或IL-2。
- 未感染个体接种后优先驱动Ag85B和ESAT-6特异性TNF-α+IL-2+CD4 T细胞出现。
- 感染个体接种后导致Ag85B特异性而非ESAT-6特异性TNF-α+IL-2+CD4 T细胞扩增。
关键数值与推荐
- 15μg H1:IC31接种两剂诱导的免疫应答幅度最大,被认为是最优方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Control of the tuberculosis epidemic requires a novel vaccine that is effective in preventing tuberculosis in adolescents, a key target population for vaccination against TB. METHODS: Healthy adolescents, stratified by M. tuberculosis-infection status, were enrolled into this observer-blinded phase II clinical trial of the protein-subunit vaccine candidate, H1:IC31, comprising a fusion protein (H1) of Ag85B and ESAT-6, formulated with the IC31 adjuvant. Local and systemic adverse events and induced T cell responses were measured after one or two administrations of either 15μg or 50μg of the H1 protein. RESULTS: Two hundred and forty participants were recruited and followed up for 224days. No notable safety events were observed regardless of H1 dose or vaccination schedule. H1:IC31 vaccination induced antigen-specific CD4 T cells, co-expressing IFN-γ, TNF-α and/or IL-2. H1:IC31 vaccination of M.tb-uninfected individuals preferentially drove the emergence of Ag85B and ESAT-6 specific TNF-α+IL-2+CD4 T cells, while H1:IC31 vaccination of M.tb-infected individuals resulted in the expansion of Ag85B-specific but not ESAT-6-specific TNF-α+IL-2+CD4 T cells. CONCLUSIONS: H1:IC31 was safe and immunogenic in uninfected and M.tb-infected adolescents. Two administrations of the 15μg H1:IC31 dose induced the greatest magnitude immune response, and was considered optimal (South African National Clinical Trials Register, DoH-27-0612-3947; Pan African Clinical Trial Registry, PACTR201403000464306).
引用
- Mearns H, Geldenhuys HD, Kagina BM, et al. H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. Vaccine. 2016. PMID: 27866772. doi:10.1016/j.vaccine.2016.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。